KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,686 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,686 shares of the company’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the transaction, the insider owned 142,547 shares in the company, valued at $2,882,300.34. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $20.87 on Tuesday. The firm has a market capitalization of $1.07 billion, a P/E ratio of -5.28 and a beta of -0.40. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The stock’s 50-day simple moving average is $17.50 and its two-hundred day simple moving average is $15.23. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $21.31.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Several sell‑side firms have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), and recent filings show large institutional stakes being established or increased — a combination that supports upward momentum and a consensus target materially above the current price. MarketBeat coverage
• Neutral Sentiment: Company fundamentals and technicals offer context: market cap ≈ $1.07B, very strong liquidity (current and quick ratios ≈7.2) and the 50‑day / 200‑day moving averages ($17.50 / $15.23) sit below the current trade — supportive background but not an immediate catalyst for price moves.
• Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares at ~$20.22; CFO Brian Piekos and other insiders also sold smaller blocks). Filings say sales were to cover tax withholding on vested awards, but concentrated insider selling can still create short‑term downward pressure or investor concern. InsiderTrades alert

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on KALV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC raised their target price on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. HC Wainwright increased their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Finally, Stifel Nicolaus increased their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.60.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $55,000. Wolverine Asset Management LLC purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $57,000. Truvestments Capital LLC increased its stake in KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.